HAYWARD, Calif., Dec. 7, 2020 /PRNewswire/ -- Benitec Biopharma,
Inc. (NASDAQ: BNTC), today announced that its 2020 Annual Meeting
of Stockholders will be held virtually on Wednesday December 9, 2020 at 3 p.m. (Pacific Time). The meeting details and
instructions on how to access the virtual meeting are provided
below:
Date:
|
Wednesday, December
9, 2020
|
Event:
|
Benitec Biopharma
2020 Annual Meeting of Stockholders
|
Time:
|
3:00 p.m. (Pacific
Time)
|
Webcast
Link:
|
www.meetingcenter.io/250254278
|
Password:
|
BNTC2020
|
Control
Number:
|
Listed on the Proxy
Card included in your proxy materials
|
The 2020 Annual Meeting of Stockholders will be held virtually
and can be accessed through the Webcast Link provided above. When
accessing the meeting you will be prompted to provide the password
listed above along with your control number listed on the Proxy
Card included in your proxy materials.
A recording of the 2020 Annual Meeting of Stockholders will be
uploaded to the Investor Relations section of the Benitec Biopharma
website.
Information about the 2020 Annual Meeting of Stockholders and
further resources can be found here: https://ir.benitec.com/
About Benitec Biopharma, Inc.
Benitec Biopharma, Inc. ("Benitec" or the "Company") is a
development-stage biotechnology company focused on the advancement
of novel genetic medicines with headquarters in Hayward, California. The proprietary platform,
called DNA-directed RNA interference, or ddRNAi, combines RNA
interference, or RNAi, with gene therapy to create medicines that
facilitate sustained silencing of disease-causing genes following a
single administration. The Company is developing ddRNAi-based
therapeutics for chronic and life-threatening human conditions
including Oculopharyngeal Muscular Dystrophy (OPMD), and Chronic
Hepatitis B. A comprehensive overview of the Company can be found
on Benitec's website at www.benitec.com.
Forward Looking Statement
Except for the historical information set forth herein, the
matters set forth in this press release include forward-looking
statements, including statements regarding Benitec's plans to
develop and commercialize its product candidates, the timing of the
initiation and completion of preclinical and clinical trials, the
timing of patient enrolment and dosing in clinical trials, the
timing of expected regulatory filings, the clinical utility and
potential attributes and benefits of ddRNAi and Benitec's product
candidates, potential future out-licenses and collaborations, the
intellectual property position and the ability to procure
additional sources of financing, and other forward-looking
statements.
These forward-looking statements are based on the Company's
current expectations and subject to risks and uncertainties that
may cause actual results to differ materially, including
unanticipated developments in and risks related to: unanticipated
delays; further research and development and the results of
clinical trials possibly being unsuccessful or insufficient to meet
applicable regulatory standards or warrant continued development;
the ability to enroll sufficient numbers of subjects in clinical
trials; determinations made by the FDA; the Company's dependence on
its relationships with its collaboration partners; the efficacy or
safety of the Company's products and the products of the Company's
collaboration partners; the acceptance of the Company's products
and the products of the Company's collaboration partners in the
marketplace; market competition; sales, marketing, manufacturing
and distribution requirements; greater than expected expenses;
expenses relating to litigation or strategic activities; and other
risks detailed from time to time in the Company's reports filed
with the Securities and Exchange Commission. The Company
disclaims any intent or obligation to update these forward-looking
statements.
Media & Investor Relations Contact:
Jay A. Morakis
CEO of M Group Strategic Communications (for Benitec Biopharma,
Inc.)
Phone: 646-859-5951
Email: jmorakis@mgroupsc.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/benitec-biopharma-announces-2020-annual-stockholder-meeting-301187645.html
SOURCE Benitec Biopharma Inc.